AXA SA vs Johnson & Johnson: Strategic Comparison

This in-depth comparison examines AXA SA and Johnson & Johnson across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AXA SA on its own, evaluating Johnson & Johnson, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AXA SA and Johnson & Johnson is widest.

On the headline numbers, AXA SA reports annual revenue of $110.2B against $85.1B for Johnson & Johnson, while their respective market capitalizations stand at $79.8B and $382.4B. AXA SA is headquartered in France and Johnson & Johnson operates from United States, and those different home markets shape how each company competes.

AXA SA: AXA maintains a natural catastrophe load of approximately 4. By 2024, that modest mutual, now known as AXA, generated EUR116 billion in gross written premiums and other revenues, served +92 million clients across 50 countries, and managed €983 billion in assets. These deals transformed AXA from a mid-tier French player into the world's second-largest insurer by 1996. The P&C segment generated €56.5 billion in gross written premiums in 2024, representing approximately 51% of total revenues. This segment is split between commercial lines (€34.9 billion), personal lines (€19.1 billion), and AXA XL Reinsurance (€2.5 billion). The all-year combined ratio for P&C was 91.0% in 2024, down 2.1 percentage points from 2023, reflecting disciplined underwriting and favorable prior-year reserve development of 1.6%. The life & savings segment contributed €52.0 billion in gross written premiums in 2024, split between life insurance (€34.5 billion) and health (€17.5 billion). However, AXA made the strategic decision in 2024 to sell AXA IM to BNP Paribas for approximately €5.1 billion, completing the transaction in July 2025. Capital management is central to AXA's core offering. In 2024, AXA paid a dividend of €2.15 per share and executed €1.8 billion in share buybacks. The Solvency II ratio of 216% provides a substantial buffer above regulatory minimums, supporting both the dividend policy and strategic flexibility. AXA is one of the world's largest and most diversified insurance groups, with a presence in 50 countries and a balanced portfolio of property & casualty, life & savings, and health insurance. The US life market is dominated by MetLife, Prudential Financial, and Northwestern Mutual, while commercial P&C is led by Chubb, Travelers, and Liberty Mutual. Gross written premiums and other revenues reached EUR116 billion, up 7% on a reported basis and 8% on a comparable basis (constant forex and scope). The P&C segment was the standout performer. Underlying earnings reached €5.5 billion, up 10%, driven by a 2.1 percentage point improvement in the combined ratio to 91.0%. The current year loss ratio excluding natural catastrophes improved by 1.0 percentage point, reflecting underwriting actions in response to 2023's elevated motor claims frequency in the UK and Germany. Prior-year reserve development was favorable at 1.6%, contributing €0.9 billion to earnings. The natural catastrophe load was 3.8% of earned premiums, below the 4.5% budget, demonstrating the impact of portfolio re-underwriting discipline. AXA XL's underlying earnings grew 29% to €2.0 billion, with a combined ratio of 91.7%. Life & health underlying earnings were €3.3 billion, up 4% on a constant exchange rate basis. Life earnings were flat at €2.6 billion, reflecting the impact of in-force transactions and market conditions. Net flows in life & health turned positive at €1.5 billion in 2024, a significant improvement from the €4.1 billion outflow in 2023, driven by strong health and protection inflows. The balance sheet remains solid. Surprisingly, Shareholders' equity was €49.9 billion at year-end 2024, and the Solvency II ratio stood at 216%, providing a substantial capital cushion. The underlying return on equity was 15.2% in 2024, up 0.3 percentage points from 2023 and above the strategic plan target range of 14-16%. The 2024 California wildfires alone contributed an estimated €0.1 billion in losses, net of reinsurance. Climate change is intensifying the frequency and severity of weather-related events, making historical loss models potentially less predictive. The combined ratio for AXA XL improved to 91.7% in 2024, demonstrating successful underwriting integration. AXA's Solvency II ratio of 216% and shareholders' equity of €49.9 billion provide substantial buffers above regulatory requirements. In Asia AXA is capitalizing on the protection gap in emerging markets and the demand for unit-linked products in developed markets like Japan and Hong Kong. AXA has implemented IT productivity and automation programs, particularly at AXA XL and in the UK & Ireland, to reduce expense ratios. Management expressed confidence in meeting these targets during the 2024 earnings presentation, citing strong operational momentum and disciplined capital management. The story of AXA begins not in a Paris boardroom but in the ashes of post-Napoleonic Normandy. In 1881, these entities merged under the name Ancienne Mutuelle, which would remain unchanged until 1977. After a stint in Canada developing life insurance business, Bébéar returned to France and was appointed general manager in 1975 following a two-month strike that paralyzed the company. This deal propelled Mutuelles Unies into the top tier of French insurers. In 1985, the group was officially renamed AXA — a name chosen because it had no meaning, was internationally pronounceable and was an easily remembered palindrome. The company targets cost operational efficiencies from acquisitions and organic efficiency improvements to support margin expansion. The P&C business is expected to remain the primary earnings driver. The company has also announced the acquisition of Nobis in Italy, strengthening its position in the Italian P&C market. The company's diversification and capital strength provide buffers against these risks, but the global insurance cycle remains a key variable. For over a century, the company — later known as Ancienne Mutuelle — remained a regional French mutual insurer. Bébéar changed the company's name to Mutuelles Unies in 1978, reflecting a new spirit of unity and ambition.

Johnson & Johnson: Johnson & Johnson began as a medical-products company in the nineteenth century and became a diversified healthcare giant. After the Kenvue separation it is a more focused healthcare company centered on medicine and medical technology.

AXA SA and Johnson & Johnson pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AXA SA and Johnson & Johnson.

AXA SA business model: AXA operates a, diversified global insurance and asset management model. Historically reliant on traditional life insurance and savings products, the modern company executed a significant, strategic pivot. It sold off its volatile, interest-rate-sensitive US life insurance business to focus almost entirely on high-margin, complex "Property & Casualty" (P&C) insurance, specifically targeting considerable global corporations and specialized commercial risks.

Johnson & Johnson business model: J&J operates a dual-engine healthcare model split into two reporting segments. Innovative Medicine (pharmaceuticals and biologics) is the larger, higher-margin business, generating $60.40 billion in 2025 (about 64% of total revenue) from blockbuster immunology, oncology, and neuroscience drugs sold primarily to healthcare systems, pharmacies, and distributors -- pricing power that comes with patent-cliff risk once exclusivity expires. MedTech (medical devices) generated $33.79 billion (about 36%), selling surgical robots, artificial joints, cardiovascular devices, and orthopedic implants directly to hospital systems, a steadier business that doesn't face the same all-or-nothing patent expiration risk. Both segments grew about 6% in 2025, taking total revenue to $94.193 billion. J&J has actively reshaped this two-segment structure through acquisitions and divestitures: it separated its consumer-health business (Band-Aid, Tylenol, Listerine) into the standalone company Kenvue in 2023 to sharpen focus on higher-margin medicine and devices, then used the resulting balance-sheet flexibility for large acquisitions including Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025). That pattern -- shedding slower-growth consumer products while buying innovation-stage drug and device makers -- has defined J&J's capital allocation for more than a decade. J&J's talc-related litigation liability, stemming from baby-powder lawsuits predating the Kenvue separation, remains a contingent financial risk investors weigh against the company's segment growth.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AXA SA stack up against those of Johnson & Johnson.

AXA SA competitive advantage: With a Solvency II ratio of 216% and an all-year P&C combined ratio of 91.0% in 2024, AXA combines scale with underwriting discipline in a way that few global insurers can match. This diversification is the company's core strategic advantage, allowing it to balance cyclical P&C underwriting with the more stable, long-duration cash flows of life and health insurance. With 156,000 employees, +92 million clients, and €983 billion in assets under management, AXA combines scale with underwriting discipline to generate consistent returns for shareholders. AXA's scale provides advantages in data and pricing sophistication, but the company must continuously invest in digital capabilities to maintain competitiveness. AXA's primary competitive advantage lies in its unmatched geographic and product diversification. Scale generates meaningful data advantages in insurance pricing and risk selection. The company's investment in digital platforms, including AI-driven claims processing and customer service automation, leverages this data advantage to reduce expense ratios and improve customer experience. The mutual company structure at the top of the AXA group provides an unique governance advantage. Capital strength is a critical competitive advantage in insurance, where the ability to pay claims during catastrophic events determines long-term viability.

Johnson & Johnson competitive advantage: Johnson & Johnson's advantage comes from scale, R&D depth, global regulatory capability, major oncology and immunology franchises, MedTech breadth, and a large commercial infrastructure.

Future prospects matter as much as current results. The growth strategies below explain how AXA SA and Johnson & Johnson each plan to expand from here.

AXA SA growth strategy: AXA is focused on commercial P&C margins, life and health growth, disciplined capital return, automation, AI-enabled efficiency, and the post-AXA IM portfolio mix.

Johnson & Johnson growth strategy: The company is investing in oncology, immunology, neuroscience, cardiovascular MedTech, electrophysiology, surgery, R&D, acquisitions, and global commercial execution.

A closer look at the financial trajectory of AXA SA and Johnson & Johnson rounds out the comparison.

AXA SA: AXA has transformed from a complex global financial conglomerate into a streamlined, high-margin commercial insurer. Under CEO Thomas Buberl, the Paris-based company generated exactly $110.2 billion in revenue and maintains a $79.8 billion market cap with exactly 147000 employees. After restructuring its volatile US life insurance business (Equitable), AXA's financial narrative in 2026 is entirely focused on profitable commercial Property and Casualty (P&C) lines and employee health benefits. The company is leveraging amounts of AI-driven telematics and localized weather data to reprice risk across its European commercial real estate and logistics portfolios.

Johnson & Johnson: Johnson & Johnson is operating as a streamlined, pure-play pharmaceutical and med-tech powerhouse following the complete spin-off of its consumer health division (Kenvue). Under CEO Joaquin Duato, the healthcare giant generated exactly $85.1 billion in revenue and maintains a $382.4 billion market cap with exactly 131900 employees. The financial narrative in 2026 is entirely defined by aggressive oncology acquisitions; desperately racing to replace revenue losses from the impending patent cliff of Stelara, J&J is deploying unprecedented billions to acquire promising antibody-drug conjugates.